SCA
HALO icon

Stuart Chaussee & Associates’s Halozyme HALO Stock Holding History

Stuart Chaussee & Associates’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-260
Closed -$3K – 79
2016
Q1 		$3K Hold
260
– – ﹤0.01% 76
2015
Q4 		$5K Buy
+260
New +$4.14K ﹤0.01% 81

Other funds holding HALO

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stuart Chaussee & Associates's HALO Position: Q2 2016 in Review

Stuart Chaussee & Associates sold out of Halozyme (HALO) in Q2 2016, closing a stake of 260 shares — an estimated $3K sold.

Stuart Chaussee & Associates first reported a position in HALO in Q4 2015 and held it in 2 quarters. The position peaked at $5K in Q4 2015. 161 funds tracked by Wall St. Rank hold HALO as of Q2 2016.

  • Stuart Chaussee & Associates reported no remaining Halozyme position as of Q2 2016 after selling out during the quarter.
  • Stuart Chaussee & Associates sold 260 Halozyme shares in Q2 2016, an estimated $3K.
  • Stuart Chaussee & Associates first reported a position in Halozyme in Q4 2015 and held it in 2 quarters.
  • Stuart Chaussee & Associates's Halozyme position peaked at $5K in Q4 2015.
  • 161 funds tracked by Wall St. Rank held Halozyme as of Q2 2016.

Based on Stuart Chaussee & Associates's 13F filing for Q2 2016, filed 12 Jul 2016.